Literature DB >> 23212918

Prolidase directly binds and activates epidermal growth factor receptor and stimulates downstream signaling.

Lu Yang1, Yun Li, Yi Ding, Kyoung-Soo Choi, A Latif Kazim, Yuesheng Zhang.   

Abstract

Prolidase, also known as Xaa-Pro dipeptidase or peptidase D (PEPD), is a ubiquitously expressed cytosolic enzyme that hydrolyzes dipeptides with proline or hydroxyproline at the carboxyl terminus. In this article, however, we demonstrate that PEPD directly binds to and activates epidermal growth factor receptor (EGFR), leading to stimulation of signaling proteins downstream of EGFR, and that such activity is neither cell-specific nor dependent on the enzymatic activity of PEPD. In line with the pro-survival and pro-proliferation activities of EGFR, PEPD stimulates DNA synthesis. We further show that PEPD activates EGFR only when it is present in the extracellular space, but that PEPD is released from injured cells and tissues and that such release appears to result in EGFR activation. PEPD differs from all known EGFR ligands in that it does not possess an epidermal growth factor (EGF) motif and is not synthesized as a transmembrane precursor, but PEPD binding to EGFR can be blocked by EGF. In conclusion, PEPD is a ligand of EGFR and presents a novel mechanism of EGFR activation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23212918      PMCID: PMC3554907          DOI: 10.1074/jbc.M112.429159

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

1.  Binding specificities and affinities of egf domains for ErbB receptors.

Authors:  J T Jones; R W Akita; M X Sliwkowski
Journal:  FEBS Lett       Date:  1999-03-26       Impact factor: 4.124

2.  Expression and molecular analysis of mutations in prolidase deficiency.

Authors:  P Ledoux; C R Scriver; P Hechtman
Journal:  Am J Hum Genet       Date:  1996-11       Impact factor: 11.025

Review 3.  The epidermal growth factor receptor and its inhibition in cancer therapy.

Authors:  J R Woodburn
Journal:  Pharmacol Ther       Date:  1999 May-Jun       Impact factor: 12.310

4.  Increased plasma concentration of epidermal growth factor in female patients with non-toxic nodular goitre.

Authors:  J Brzeziński; A Lewiński
Journal:  Eur J Endocrinol       Date:  1998-04       Impact factor: 6.664

5.  Prolidase deficiency in two siblings with chronic leg ulcerations. Clinical, biochemical, and morphologic aspects.

Authors:  A Leoni; G Cetta; R Tenni; I Pasquali-Ronchetti; F Bertolini; D Guerra; K Dyne; A Castellani
Journal:  Arch Dermatol       Date:  1987-04

6.  Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2).

Authors:  M Oshima; J E Dinchuk; S L Kargman; H Oshima; B Hancock; E Kwong; J M Trzaskos; J F Evans; M M Taketo
Journal:  Cell       Date:  1996-11-29       Impact factor: 41.582

7.  Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells.

Authors:  Jung-Hwan Yoon; Geum-Youn Gwak; Hyo-Suk Lee; Steven F Bronk; Nathan W Werneburg; Gregory J Gores
Journal:  J Hepatol       Date:  2004-11       Impact factor: 25.083

8.  Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression.

Authors:  Russell D Klein; Carolyn S Van Pelt; Anita L Sabichi; Jorge Dela Cerda; Susan M Fischer; Gerhard Fürstenberger; Karin Müller-Decker
Journal:  Cancer Res       Date:  2005-03-01       Impact factor: 12.701

9.  Epidermal growth factor measurements in mouse plasma: method, ontogeny, and sex difference.

Authors:  J Perheentupa; J Lakshmanan; S B Hoath; U Beri; H Kim; T Macaso; D A Fisher
Journal:  Am J Physiol       Date:  1985-04

10.  Hepatocyte growth factor inhibits anoikis by induction of activator protein 1-dependent cyclooxygenase-2. Implication in head and neck squamous cell carcinoma progression.

Authors:  Qinghua Zeng; Laurie K McCauley; Cun-Yu Wang
Journal:  J Biol Chem       Date:  2002-10-18       Impact factor: 5.157

View more
  20 in total

1.  Functional Screening of Candidate Causal Genes for Insulin Resistance in Human Preadipocytes and Adipocytes.

Authors:  Zhifen Chen; Haojie Yu; Xu Shi; Curtis R Warren; Luca A Lotta; Max Friesen; Torsten B Meissner; Claudia Langenberg; Martin Wabitsch; Nick Wareham; Mark D Benson; Rob E Gerszten; Chad A Cowan
Journal:  Circ Res       Date:  2019-11-19       Impact factor: 17.367

2.  Dysregulation of macrophage PEPD in obesity determines adipose tissue fibro-inflammation and insulin resistance.

Authors:  V Pellegrinelli; S Rodriguez-Cuenca; C Rouault; E Figueroa-Juarez; H Schilbert; S Virtue; J M Moreno-Navarrete; G Bidault; M C Vázquez-Borrego; A R Dias; B Pucker; M Dale; M Campbell; S Carobbio; Y H Lin; M Vacca; J Aron-Wisnewsky; S Mora; M M Masiero; A Emmanouilidou; S Mukhopadhyay; G Dougan; M den Hoed; R J F Loos; J M Fernández-Real; D Chiarugi; K Clément; A Vidal-Puig
Journal:  Nat Metab       Date:  2022-04-25

3.  Prolidase is required for early trafficking events during influenza A virus entry.

Authors:  Marie O Pohl; Thomas O Edinger; Silke Stertz
Journal:  J Virol       Date:  2014-07-16       Impact factor: 5.103

4.  Inhibition of ERBB2-overexpressing Tumors by Recombinant Human Prolidase and Its Enzymatically Inactive Mutant.

Authors:  Lu Yang; Yun Li; Arup Bhattacharya; Yuesheng Zhang
Journal:  EBioMedicine       Date:  2015-05-01       Impact factor: 8.143

5.  A plasma proteolysis pathway comprising blood coagulation proteases.

Authors:  Lu Yang; Yun Li; Arup Bhattacharya; Yuesheng Zhang
Journal:  Oncotarget       Date:  2016-07-05

6.  Exogenous proline stimulates type I collagen and HIF-1α expression and the process is attenuated by glutamine in human skin fibroblasts.

Authors:  Lukasz Szoka; Ewa Karna; Kornelia Hlebowicz-Sarat; Jacek Karaszewski; Jerzy A Palka
Journal:  Mol Cell Biochem       Date:  2017-05-19       Impact factor: 3.396

Review 7.  The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance.

Authors:  Yuesheng Zhang
Journal:  Pharmacol Ther       Date:  2020-09-06       Impact factor: 12.310

8.  Quantitative analysis of the natural history of prolidase deficiency: description of 17 families and systematic review of published cases.

Authors:  Francis Rossignol; Marvid S Duarte Moreno; Carlos R Ferreira; Manuel Schiff; Jean-François Benoist; Manfred Boehm; Emmanuelle Bourrat; Aline Cano; Brigitte Chabrol; Claudine Cosson; José Luís Dapena Díaz; Arthur D'Harlingue; David Dimmock; Alexandra F Freeman; María Tallón García; Cheryl Garganta; Tobias Goerge; Sara S Halbach; Jan de Laffolie; Christina T Lam; Ludovic Martin; Esmeralda Martins; Andrea Meinhardt; Isabelle Melki; Amanda K Ombrello; Noémie Pérez; Dulce Quelhas; Anna Scott; Anne M Slavotinek; Ana Rita Soares; Sarah L Stein; Kira Süßmuth; Jenny Thies
Journal:  Genet Med       Date:  2021-05-26       Impact factor: 8.822

9.  Identification of prolidase as a high affinity ligand of the ErbB2 receptor and its regulation of ErbB2 signaling and cell growth.

Authors:  L Yang; Y Li; Y Zhang
Journal:  Cell Death Dis       Date:  2014-05-08       Impact factor: 8.469

10.  Dual inhibition of ErbB1 and ErbB2 in cancer by recombinant human prolidase mutant hPEPD-G278D.

Authors:  Lu Yang; Yun Li; Arup Bhattacharya; Yuesheng Zhang
Journal:  Oncotarget       Date:  2016-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.